Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma Journal Article
| Authors: | Dauer, L. T.; St. Germain, J.; Williamson, M. J.; Zanzonico, P.; Modak, S.; Cheung, N. K.; Divgi, C. |
| Article Title: | Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma |
| Abstract: | The purpose of this retrospective study was to evaluate the whole-body clearance kinetics of I-3F8 monoclonal antibody, an anti-ganglioside 2 antibody, used in the treatment of pediatric patients with late-stage neuroblastoma (NB). Serial whole-body dose rate measurements were obtained on pediatric patients participating in phase I dose escalation studies of therapeutic I-3F8. Whole-body retention fractions were derived and fit for each treatment to exponential curves to determine both the effective half-lives and corresponding clearance fractions. 27 patients were administered I-3F8 over the course of cyclical administrations with a median administered activity of 2.5 GBq (range, 1-8.14 GBq), typically every 2-4 d for up to 9 treatment cycles. Based on whole-body dose rate measurements, there was a large variability in the calculated mono-exponential clearance effective half-life time, with a mean of 26.4 h (range, 12.4-45.5 h). The data from a subset of 12 treatments were fit to a bi-exponential curve with a rapid clearance component mean effective half-time of 16.9 h (range, 4.3-26 h) and a slower clearance component mean effective half-time of 65.5 h (range, 16.9-136 h). The use of whole-body dose rate measurements, obtained for patient-release and other radiation safety considerations, can be useful in estimating whole-body clearance kinetics for photon emitting radionuclide labeled mAbs and other therapeutic radiopharmaceuticals. In the case of I-3F8 for pediatric NB therapy, the demonstrated variability in effective half-time suggests the need for patient-specific tracer dosimetry for both optimization of treatment and radiation safety precaution decision-making. Copyright © 2006 Health Physics Society. |
| Keywords: | adolescent; adult; child; child, preschool; retrospective studies; radiation dose; radiopharmaceuticals; radiotherapy dosage; retrospective study; monoclonal antibody; antibodies, monoclonal; kinetics; immunoglobulin g; iodine 131; iodine radioisotopes; neuroblastoma; dosimetry; immunoprecipitation; metabolic clearance rate; radiation therapy; relative biological effectiveness; body burden; radioimmunotherapy; whole-body counting; dose calculation; half-life; monoclonal antibody 3f8; radiation protection; photon emission tomography; 131i |
| Journal Title: | Health Physics |
| Volume: | 92 |
| Issue: | 1 |
| ISSN: | 0017-9078 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2007-01-01 |
| Start Page: | 33 |
| End Page: | 39 |
| Language: | English |
| DOI: | 10.1097/01.HP.0000231583.32904.6c |
| PUBMED: | 17164597 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 5" - "Export Date: 17 November 2011" - "CODEN: HLTPA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
648Cheung -
163Divgi -
249Modak -
355Zanzonico -
170Dauer -
61St Germain -
27
Williamson
Related MSK Work